Clinical Trials Logo
  1. Home
  2. Stomatitis
  3. NCT00041665

Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy

Stomatitis Clinical Trial

Official title:
A Phase 3, Randomized, Double-blind, Placebo-controlled Trial of Recombinant Human Keratinocyte Growth Factor for Reduction of Mucositis in Patients With Hematologic Malignancies Undergoing Total Body Irradiation and High-dose Chemotherapy With Autologous PBPC Transplantation

Clinical Trial Summary

Radiotherapy and high dose chemotherapy with bone marrow transplantation or peripheral blood stem cell transplantation is frequently used as treatment for patients with cancers of the bone marrow or lymph nodes such as Hodgkin's disease, non-Hodgkin's lymphoma, leukemia or multiple myeloma. A common side effect of the radiotherapy and high dose chemotherapy is mucositis (inflammation of the inside of the mouth and throat resulting in pain and difficulty swallowing). Mucositis is often very severe such that patients receive intravenous nutrition and pain medication in the hospital.

In this study, an investigational recombinant human growth factor called Keratinocyte Growth Factor (rHuKGF) is being evaluated to determine its protective effect on the mucosal tissue and its ability to reduce the mouth and throat soreness.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00041665
Study type Interventional
Source Amgen
Contact
Status Completed
Phase Phase 3
View Details
See also
  Status Clinical Trial Phase
Completed NCT02229136 - Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus Phase 2
Completed NCT02762019 - Laser for Oral Mucositis in Pediatric Onco-hematology Phase 3
Recruiting NCT02945878 - Predictive Factors of Acute Oral Mucositis Induced by Chemo-radiotherapy for Local Advanced Nasopharyngeal Carcinoma N/A
Recruiting NCT05878405 - Methylene Blue Mouthwash for the Treatment of Oral Mucositis Pain in Patients With Cancer Phase 3
Completed NCT00323518 - A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis Phase 2
Terminated NCT02326675 - Cryotherapy in the Prevention of Chemotherapy-Induced Mucositis in Stem Cell Transplant N/A
Active, not recruiting NCT01099891 - The Clinical Study for Evaluation of Efficacy and Safety of EGF on Oral Mucositis in Radiation Therapy Patients Phase 3
Terminated NCT01092975 - Safety of Phenylephrine for Oral Mucositis Prevention Phase 1
Terminated NCT00031551 - Evaluation of Efficacy and Mechanisms of an Antiinflammatory Intervention for Chemotherapy Related Mucosal Injury Phase 2
Completed NCT00385515 - Efficacy of SNX-1012 in the Treatment of Oral Mucositis Phase 2
Completed NCT03200340 - EC-18 for Oral Mucositis in Patients With Concomitant Chemoirradiation Phase 2
Not yet recruiting NCT05323058 - The Use of Tulsi Extract for The Management of Oral Mucositis in Head & Neck Cancer Patients Undergoing Radiotherapy Phase 2
Completed NCT01837446 - Morphine Mouthwash for Management of Oral Mucositis in Patients With Head and Neck Cancer Phase 2/Phase 3
Completed NCT00104065 - Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant Phase 2
Completed NCT03469284 - MOM's PAIN (Methylene Blue for Oral Mucositis' PAIN) Phase 2
Not yet recruiting NCT03778008 - Recombinant Bovine Basic Fibroblast Growth Factor for the Treatment of Radiation Induced Oral Mucositis Phase 2
Terminated NCT00075023 - Effectiveness of Topical Thalidomide to Treat Chronic Graft-Versus-Host-Disease Related Stomatitis Phase 2
Not yet recruiting NCT05010928 - Using Tea-based Mouthwash Relieve Stomatitis and Oral Ulcers Phase 2
Completed NCT02407834 - Effectiveness of Hygiene Solutions on Denture Biofilm Phase 4
Active, not recruiting NCT00101582 - Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Phase 3